Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 11, 2012 - Issue 6
Submit an article Journal homepage
479
Views
19
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Safety and efficacy evaluation of ambrisentan in pulmonary hypertension

Carmine Dario Vizza“Sapienza” University of Rome, Department of Cardiovascular and Respiratory Disease, Rome, Italy;“Sapienza” University of Rome, Department of Cardiovascular and Respiratory Disease, Rome, Italy
, MD,
Francesco Fedele“Sapienza” University of Rome, Department of Cardiovascular and Respiratory Disease, Rome, Italy;“Sapienza” University of Rome, Department of Cardiovascular and Respiratory Disease, Rome, Italy
, MD,
Beatrice Pezzuto“Sapienza” University of Rome, Department of Cardiovascular and Respiratory Disease, Rome, Italy;“Sapienza” University of Rome, Department of Cardiovascular and Respiratory Disease, Rome, Italy
, MD &
Lewis J. RubinUniversity of California, San Diego School of Medicine, Division of Pulmonary and Critical Care Medicine, La Jolla, CA, USA;[email protected];University of California, San Diego School of Medicine, Division of Pulmonary and Critical Care Medicine, La Jolla, CA, USA
Pages 1003-1011 | Published online: 04 Aug 2012

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Tian Lan, Ping Fang, Xuemei Ye, Xia Lan & Ren-ai Xu. (2021) Evaluation of herb-drug interaction of ambrisentan with shikonin based on UPLC-MS/MS. Pharmaceutical Biology 59:1, pages 1131-1136.
Read now
Hayakazu Sumida, Yoshihide Asano, Masaru Hatano, Naohiko Aozasa, Tetsuo Toyama, Kaname Akamata, Miki Miyazaki, Takashi Taniguchi, Takehiro Takahashi, Yohei Ichimura, Shinji Noda, Yoshihiro Kuwano, Koichi Yanaba & Shinichi Sato. (2016) Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis. Modern Rheumatology 26:3, pages 454-457.
Read now
Andrew J. Peacock, William Zamboni & Carmine Dario Vizza. (2015) Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. Current Medical Research and Opinion 31:9, pages 1793-1807.
Read now
Giuseppe Murdaca, Francesca Spanò & Francesco Puppo. (2014) Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opinion on Drug Safety 13:3, pages 295-305.
Read now

Articles from other publishers (15)

Ruiqi Liu, Tianyi Yuan, Ranran Wang, Difei Gong, Shoubao Wang, Guanhua Du & Lianhua Fang. (2023) Insights into Endothelin Receptors in Pulmonary Hypertension. International Journal of Molecular Sciences 24:12, pages 10206.
Crossref
Kavya Surendran, BeenuMaria Joseph & JobinKunjumon Vilapurathu. (2023) A case report on ambrisentan-induced angioedema. Annals of Clinical Cardiology 5:1, pages 45.
Crossref
Christoph Tabeling, Carla R. González Calera, Jasmin Lienau, Jakob Höppner, Thomas Tschernig, Olivia Kershaw, Birgitt Gutbier, Jan Naujoks, Julia Herbert, Bastian Opitz, Achim D. Gruber, Berthold Hocher, Norbert Suttorp, Harald Heidecke, Gerd-R. Burmester, Gabriela Riemekasten, Elise Siegert, Wolfgang M. Kuebler & Martin Witzenrath. (2022) Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension. Frontiers in Immunology 13.
Crossref
Katrina M Mirabito Colafella, Karla B Neves, Augusto C Montezano, Ingrid M Garrelds, Richard van Veghel, René de Vries, Estrellita Uijl, Hans J Baelde, Anton H van den Meiracker, Rhian M Touyz, A H Jan Danser & Jorie Versmissen. (2020) Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats. Cardiovascular Research 116:10, pages 1779-1790.
Crossref
Jamshed Haneef, Datta Markad & Renu Chadha. (2020) Interaction Map Driven Cocrystallization of Ambrisentan: Structural and Biopharmaceutical Evaluation. Crystal Growth & Design 20:7, pages 4612-4620.
Crossref
Jamshed Haneef & Renu Chadha. (2020) Sustainable synthesis of ambrisentan – syringic acid cocrystal: employing mechanochemistry in the development of novel pharmaceutical solid form. CrystEngComm 22:14, pages 2507-2516.
Crossref
Zixuan Pan, Alberto M. Marra, Nicola Benjamin, Christina A. Eichstaedt, Norbert Blank, Eduardo Bossone, Antonio Cittadini, Gerry Coghlan, Christopher P. Denton, Oliver Distler, Benjamin Egenlauf, Christine Fischer, Satenik Harutyunova, Panagiota Xanthouli, Hanns-Martin Lorenz & Ekkehard Grünig. (2019) Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Research & Therapy 21:1.
Crossref
Katherine A. Lyseng-Williamson & Jürgen Behr. (2018) Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. Drugs & Therapy Perspectives 34:7, pages 289-299.
Crossref
Jamshed Haneef, Renu Chadha, Vijay Gupta & Sanjay K. Mandal. (2018) Novel polymorph of ambrisentan: Characterization and stability. Journal of Pharmaceutical and Biomedical Analysis 153, pages 102-109.
Crossref
Anthony P. Davenport, Kelly A. Hyndman, Neeraj Dhaun, Christopher Southan, Donald E. Kohan, Jennifer S. Pollock, David M. Pollock, David J. Webb & Janet J. Maguire. (2016) Endothelin. Pharmacological Reviews 68:2, pages 357-418.
Crossref
Jürgen Behr & Katherine A. Lyseng-Williamson. (2016) Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU. Drugs & Therapy Perspectives 32:2, pages 50-59.
Crossref
Xue-Qin Li, Yun-Jing Li & Yong Wang. (2015) Ambrisentan May Improve Exercise Tolerance and Cardiac Function in Patients With Pulmonary Hypertension. Clinical Therapeutics 37:6, pages 1270-1279.
Crossref
Janet J. Maguire & Anthony P. Davenport. (2015) Endothelin Receptors and Their Antagonists. Seminars in Nephrology 35:2, pages 125-136.
Crossref
Hironori Muraoka, Teruhiko Imamura, Masaru Hatano, Hisataka Maki, Atsushi Yao, Koichiro Kinugawa & Issei Komuro. (2015) Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect. International Heart Journal 56:4, pages 471-473.
Crossref
Shikha Patel, Xingjian Liu, Ming Liu, Ralph Stephani, Hardik Patel & Jerome Cantor. (2014) HJP272, A Novel Endothelin Receptor Antagonist, Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Hamsters. Lung 192:5, pages 803-810.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.